The Tema Obesity & Cardiometabolic ETF (HRTS) is a fund focused on companies involved in the development of treatments for obesity and cardiometabolic diseases, with a diversified portfolio of 46 companies. Maurits Pot, CEO of Tema ETFs, which issues this ETF, highlights an investment strategy that goes beyond traditional market players such as Novo Nordisk and Eli Lilly. The group aims to capitalise on innovative companies in the development phase, in response to a potentially colossal market driven by the global prevalence of obesity.
Bloomberg TV provided by MT Newswires
